Loading…
TransMedics Group, Inc. is projected to rise to $93.89 by 2027, a +23% move from its current price of $76.13. TMDX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $74.21 | $76.12 | $78.09 | -0.01% |
| Aug 2 | $73.42 | $76.11 | $78.91 | -0.02% |
| Aug 3 | $72.82 | $76.10 | $79.54 | -0.03% |
| Aug 4 | $72.32 | $76.10 | $80.07 | -0.04% |
| Aug 5 | $71.87 | $76.09 | $80.55 | -0.06% |
| Aug 6 | $71.48 | $76.08 | $80.98 | -0.07% |
| Aug 7 | $71.11 | $76.07 | $81.37 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $71.11 | $76.07 | $81.37 | -0.08% |
| Week 2 | $69.10 | $76.01 | $83.61 | -0.16% |
| Week 3 | $67.58 | $75.95 | $85.36 | -0.23% |
| Week 4 | $66.32 | $75.89 | $86.84 | -0.31% |
| Week 5 | $65.22 | $75.83 | $88.17 | -0.39% |
| Week 6 | $64.24 | $75.77 | $89.38 | -0.47% |
| Week 7 | $63.35 | $75.71 | $90.49 | -0.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TransMedics Group, Inc. is a commercial-stage medical technology company in the Healthcare sector. It engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that replicates near-physiologic conditions for donor organs outside the human body. OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
It also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc. trades as TMDX in the Healthcare sector. Its current price is $75.38 and its market cap is $2.61B. It is ranked 1870.
The 2026 forecast shows a neutral starting point with min $62.04, avg $75.38, max $96.14. From 2027 onward, the outlook shifts toward bullish momentum, with rising averages through 2030 and beyond. By 2040 the forecasted average is $180.80 and by 2050 it is $362.10, with the max forecast reaching $698.34.
A major floor 19.3% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
The nearest ceiling, 3.5% above — a clean break opens room to run.
A major ceiling 52.5% above — clearing it would confirm fresh momentum.
Key TMDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TMDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $75.39 | Buy | $75.65 | Buy |
| MA 10 | $74.10 | Buy | $74.73 | Buy |
| MA 20 | $73.39 | Buy | $73.92 | Buy |
| MA 50 | $72.13 | Buy | $76.52 | Sell |
| MA 100 | $87.34 | Sell | $86.42 | Sell |
| MA 200 | $109.29 | Sell | $97.99 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.08 | Neutral |
| Stoch RSI (14) | 67.35 | Neutral |
| CCI (20) | 87.57 | Neutral |
| Williams %R (14) | -27.22 | Info |
| MACD (12,26,9) | 0.53 | Buy |
| ROC (12) | 2.06 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 72.78 | Neutral |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | 2.09 | Buy |
| Ultimate (7,14,28) | 57.18 | Neutral |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 77.58 | Sell |
| ADX (14) | 10.58 | Neutral |
| ATR (14) | 1.70 | Info |
The 30-day technical picture is labeled bullish. RSI14 is 50, and the price action is viewed in a positive light despite a neutral RSI reading. The 50-day moving average sits at $71.62, while the 200-day moving average sits at $111.47. Support is identified at $66.42 and resistance at $78.79.
The 30-day price range spans $61.65 to $92.16, indicating some near-term volatility. Annualized volatility is high at 60%, underscoring notable risk alongside the recent bullish tilt.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $62.04 | $76.13 | $98.23 | 0% | Neutral | |
| $75.32 | $93.89 | $123.43 | +23% | Bullish | |
| $81.76 | $104.61 | $142.48 | +37% | Bullish | |
| $86.77 | $113.44 | $158.83 | +49% | Bullish | |
| $89.22 | $118.87 | $170.34 | +56% | Bullish | |
| $88.96 | $120.58 | $176.32 | +58% | Bullish | |
| $92.26 | $127.07 | $189.22 | +67% | Bullish | |
| $93.32 | $130.47 | $197.50 | +71% | Bullish | |
| $109.97 | $155.95 | $239.66 | +105% | Bullish | |
| $127.95 | $183.93 | $286.65 | +142% | Bullish | |
| $142.40 | $217.64 | $359.77 | +186% | Bullish | |
| $260.78 | $442.53 | $797.27 | +481% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $62.04 | $76.13 | $88.80 | +0.00% |
| August 2026 | $65.81 | $77.13 | $92.42 | +1.31% |
| September 2026 | $63.80 | $75.36 | $91.44 | -2.30% |
| October 2026 | $63.06 | $74.95 | $91.85 | -0.54% |
| November 2026 | $65.12 | $77.79 | $96.09 | +3.79% |
| December 2026 | $65.78 | $78.95 | $98.23 | +1.49% |
Click any year to see its month-by-month TMDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
TransMedics Group, Inc.'s 2026 outlook centres on $76.13, within a $62.04 to $98.23 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TMDX could reach as high as $123.43, with a base case around $93.89 and support toward $75.32 — roughly +23% from $76.13. Buyers look set to stay in control over this stretch.
Expect TMDX to range from $81.76 to $142.48 through 2028. The $104.61 average target implies a +37% move from current prices. That is up +11% on the projected 2027 average. Momentum favours further upside here.
The TMDX price prediction for 2029 points to an average of $113.44 (low $86.77, high $158.83) — a potential gain of +49% on today's $76.13. Buyers look set to stay in control over this stretch.
In 2030, TMDX is projected to trade between $89.22 and $170.34, averaging $118.87 — a potential gain of +56% from today's $76.13. That is up +5% on the projected 2029 average. Momentum favours further upside here.
TransMedics Group, Inc.'s 2031 outlook centres on $120.58, within a $88.96 to $176.32 range. That is up +1% on the projected 2030 average. That marks a +58% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TMDX could reach as high as $189.22, with a base case around $127.07 and support toward $92.26 — roughly +67% from $76.13. Momentum favours further upside here.
Expect TMDX to range from $93.32 to $197.50 through 2033. The $130.47 average target implies a +71% move from current prices. That is up +3% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TMDX price prediction for 2034 points to an average of $155.95 (low $109.97, high $239.66) — a potential gain of +105% on today's $76.13. Momentum favours further upside here.
In 2035, TMDX is projected to trade between $127.95 and $286.65, averaging $183.93 — a potential gain of +142% from today's $76.13. That is up +18% on the projected 2034 average. Buyers look set to stay in control over this stretch.
TransMedics Group, Inc.'s 2040 outlook centres on $217.64, within a $142.40 to $359.77 range. That is up +18% on the projected 2035 average. That marks a +186% change versus current levels. Momentum favours further upside here.
By 2050, TMDX could reach as high as $797.27, with a base case around $442.53 and support toward $260.78 — roughly +481% from $76.13. Buyers look set to stay in control over this stretch.
Investing $1,000 in TMDX today (≈ 13.135426 TMDX) could be worth
$5,812.82
+$4,812.82 (+481%) by 2050 · US Dollar
Based on the average projected TMDX price of $442.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TMDXwould be worth at today's price.
$1,000 invested in TMDX on Jul 30, 2025 (≈ 9.285051 TMDX) would be worth
$706.87
-$293.13 (-29.3%) today · 0.71× · US Dollar
Based on a TMDX entry price of $107.7 vs. today's $76.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $71.13 | $1,070.29 | +7.0% |
| 1 month ago | $66.42 | $1,146.19 | +14.6% |
| 3 months ago | $100.01 | $761.22 | -23.9% |
| 6 months ago | $133.98 | $568.24 | -43.2% |
| 1 year ago | $107.7 | $706.87 | -29.3% |
| All time (5.0y) ago | $28.77 | $2,646.16 | +164.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TMDX forecast.
Our base-case forecast reaches $150.00 around 2034.
Implied market cap at $150.00: $5.18B
Across the multi-year forecast, the average price progressively rises from a 2026 baseline to significantly higher levels. The 2026 min is $62.04, the avg is $75.38, the max is $96.14, with an initial neutral sentiment. In 2027 the avg advances to $90.45 and the max to $121.91, with ROI of 20 and a neutral stance.
In 2028 the avg is $101.47 and the max is $142.45 (ROI 34.6, sentiment BULLISH), and in 2029 the avg is $106.40 with a max of $154.20 (ROI 41.2, sentiment BULLISH). By 2030 the avg is $112.26 and the max is $167.07 (ROI 48.9, sentiment BULLISH).
From 2031 through 2033 the forecast shows continued bullish momentum with avg prices around $110.71–$114.72 and max prices near $168.63–$181.77, with ROIs in the mid-40s to low-50s range. The 2034 forecast rises to an avg of $137.17 and max $221.12 (ROI 82, sentiment BULLISH), and 2035 shows an avg of $160.20 and max $262.41 (ROI 112.5, sentiment BULLISH).
Longer-term projections remain strongly bullish, with 2040 avg $180.80 and max $316.59 (ROI 139.9, sentiment BULLISH), and 2050 avg $362.10 with a max of $698.34 (ROI 380.4, sentiment BULLISH). These figures illustrate an upward trajectory with substantial upside potential alongside rising risk and uncertainty inherent in longer-horizon forecasts.
Tap a question to reveal the answer.
The forecast for 2030 shows min $81.54, avg $112.26, max $167.07 with ROI 48.9 and sentiment BULLISH.
The forecast shows a bullish trajectory from 2027 onward, with increasing average prices and ROIs (20 in 2027, 34.6 in 2028, 41.2 in 2029, 48.9 in 2030, 139.9 in 2040, 380.4 in 2050). These are estimates and not guarantees.
Yes. The max forecast reaches $221.12 in 2034 and $262.41 in 2035, indicating the potential to exceed $200.
Current price: $75.38. Market cap: $2.61B.
The 30-day range is $61.65 to $92.16, with support at $66.42 and resistance at $78.79. The RSI14 is 50, and the SMA50 is $71.62 while the SMA200 is $111.47, indicating a bullish longer-term bias with near-term volatility.
TransMedics Group, Inc. Community Discussion
0Share your TransMedics Group, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.